Evolus (EOLS) Gross Profit Growth (3y) (2022 - 2026)
Evolus (EOLS) Gross Profit Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 7.62% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 4.71% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -7.64% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 12.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -9.13% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 24.80% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 0.95% |
| 10 | Evolus | 403.51 Mn | 353.71 Mn | 48.90 Mn | 18.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.25% |
| Dec 31, 2025 | 29.47% |
| Sep 30, 2025 | 30.96% |
| Jun 30, 2025 | 28.53% |
| Mar 31, 2025 | 31.11% |
| Dec 31, 2024 | 40.88% |
| Sep 30, 2024 | 40.48% |
| Jun 30, 2024 | 47.07% |
| Mar 31, 2024 | 76.77% |
| Dec 31, 2023 | 42.86% |
| Sep 30, 2023 | 39.26% |
| Jun 30, 2023 | 80.82% |
| Mar 31, 2023 | 67.65% |
| Dec 31, 2022 | 20.00% |
| Sep 30, 2022 | 29.26% |
| Jun 30, 2022 | 134.70% |